Oncology | Phase II Developments | GERMANY

Boehringer Ingelheim GmbH

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

G1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib

Lead Product(s): Trilaciclib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: G1 Therapeutics, Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 30, 2020

Details:

G1 and Boehringer Ingelheim will collaborate on the commercialization of trilaciclib for its first potential indication in small cell lung cancer, with the B.I's oncology commercial team, well-established in lung cancer, leading sales force engagement initiatives.

Affimed

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting

Lead Product(s): AFM13

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 29, 2020

Details:

REDIRECT is a Registration-directed Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with Relapsed or Refractory CD30 positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT).

MorphoSys

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

MorphoSys and Incyte Announce Long-term Follow-up Results from L-MIND Study of Tafasitamab in Patients with r/r DLBCL

Lead Product(s): Tafasitamab,Lenalidomide

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 14, 2020

Details:

After a minimum of two years' follow-up, outcomes from the L-MIND study are consistent with the primary analysis and confirm the durability of the response and overall survival of tafasitamab in combination with lenalidomide followed by tafasitamab monotherapy.

Bayer HealthCare

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific Program

Lead Product(s): Radium-223,Niraparib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 11, 2020

Details:

Presentation showcases data on final analysis of overall survival (OS) from the Phase III ARAMIS trial investigating darolutamide in men with non-metastatic castration-resistant prostate cancer.

Affimed

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma

Lead Product(s): AFM13

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 01, 2020

Details:

U.S. FDA has granted orphan drug designation to AFM13, its lead CD30- and CD16A-binding innate cell engager, for the treatment of patients with T-cell lymphoma.

MorphoSys

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

MorphoSys Initiates Expanded Access Program for Tafasitamab

Lead Product(s): Tafasitamab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 04, 2020

Details:

The EAP may provide access to tafasitamab for use in patients with relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL) in combination with lenalidomide.

Qiagen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

QIAGEN Builds on Global Collaboration With Amgen for Companion Diagnostic Development in Non-small Cell Lung Cancer

Lead Product(s): AMG510

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Amgen Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 13, 2020

Details:

QIAGEN and Amgen to develop tissue-based therascreen® test, paired with investigational treatment AMG 510, to identify patients whose cancers have KRAS G12C mutation.

Find

Find Oncology Drugs in Phase II Clinical Development in GERMANY

Germany

Product Type

Companies

Boehringer Ingelheim GmbH

G1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib

Affimed

Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting

MorphoSys

MorphoSys and Incyte Announce Long-term Follow-up Results from L-MIND Study of Tafasitamab in Patients with r/r DLBCL

Bayer HealthCare

Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific Program

Affimed

Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma

MorphoSys

MorphoSys Initiates Expanded Access Program for Tafasitamab

Qiagen

QIAGEN Builds on Global Collaboration With Amgen for Companion Diagnostic Development in Non-small Cell Lung Cancer